AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ROCKET PHARMACEUTICALS, INC. Director's Dealing 2024

Oct 29, 2024

33148_dirs_2024-10-29_59d36e65-4ee5-45fc-9b60-31dac307b694.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2024-09-26

Reporting Person: Makker Gotham (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-09-26	Stock Option (Right to Buy)	$17.6	A	204	Acquired	2034-09-26	Common Stock (204)	Direct
2024-09-26	Stock Option (Right to Buy)	$17.6	A	303	Acquired	2034-09-26	Common Stock (303)	Direct

Footnotes

F1: This option represents a right to purchase a total of 204 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on September 26, 2025.

F2: This option represents a right to purchase a total of 303 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on September 26, 2025.